Kena C Miller
Overview
Explore the profile of Kena C Miller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yopp A, Wall H, Miller K
J Adv Pract Oncol
. 2018 Apr;
7(7):748-754.
PMID: 29670810
No abstract available.
2.
Paulus A, Masood A, Miller K, Khan A, Akhtar D, Advani P, et al.
Br J Haematol
. 2014 Jan;
165(1):78-88.
PMID: 24467634
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in the U.S. The course of the disease has been shown to be negatively impacted by increased levels of BCL2....
3.
Paulus A, Chitta K, Akhtar S, Personett D, Miller K, Thompson K, et al.
Br J Haematol
. 2013 Nov;
164(3):352-365.
PMID: 24236538
Multiple myeloma, the second most common haematological malignancy in the U.S., is currently incurable. Disruption of the intrinsic apoptotic pathway by BCL2 and MCL1 upregulation is observed in >80% of...
4.
Chitta K, Khan A, Ersing N, Swaika A, Masood A, Paulus A, et al.
Leuk Lymphoma
. 2013 Jun;
55(3):652-61.
PMID: 23721511
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is currently incurable. To expand the therapeutic armamentarium, we investigated neem leaf extract (NLE) after a patient with CLL...
5.
Chitta K, Paulus A, Ailawadhi S, Foster B, Moser M, Starostik P, et al.
Leuk Lymphoma
. 2012 Jul;
54(2):387-96.
PMID: 22812491
Understanding the biology of Waldenström macroglobulinemia is hindered by a lack of preclinical models. We report a novel cell line, RPCI-WM1, from a patient treated for WM. The cell line...
6.
Smonskey M, Block A, Deeb G, Chanan-Khan A, Bernstein Z, Miller K, et al.
Am J Clin Pathol
. 2012 Mar;
137(4):641-6.
PMID: 22431542
Deletion of 13q14.3 (del(13q)) is the most common cytogenetic abnormality in chronic lymphocytic leukemia (CLL) and implies a favorable prognosis. We explored the feasibility of detecting del(13q) by real-time quantitative...
7.
Swaika A, Paulus A, Miller K, Sher T, Almyroudis N, Ball D, et al.
J Support Oncol
. 2012 Jan;
10(4):155-9.
PMID: 22222250
Background: Previous studies have indicated that, in patients with multiple myeloma (MM), bortezomib is associated with an increased incidence of herpes zoster, resulting from reactivation of latent varicella zoster virus...
8.
Masood A, Chitta K, Paulus A, Khan A, Sher T, Ersing N, et al.
Br J Haematol
. 2011 Dec;
157(1):59-66.
PMID: 22171982
Over-expression of anti-apoptotic BCL2 has been reported in chronic lymphocytic leukaemia (CLL), but targeting BCL2 alone did not yield appreciable clinical results. However, it was demonstrated that BCL2 inhibitors enhanced...
9.
Masood A, Sher T, Paulus A, Miller K, Chitta K, Chanan-Khan A
Onco Targets Ther
. 2011 Dec;
4:169-83.
PMID: 22162923
The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone...
10.
Sher T, Ailawadhi S, Miller K, Manfredi D, Wood M, Tan W, et al.
Br J Haematol
. 2011 May;
154(1):104-10.
PMID: 21554260
Novel agents have provided a new foundation for multiple myeloma therapies. When combined with other anti-myeloma agents, these compounds significantly enhance clinical efficacy. High-dose steroids are frequently used in anti-myeloma...